All Updates

All Updates

icon
Filter
Partnerships
Clearmind Medicine partners with IMP Clinical Supply Services
Psychedelic Medicine
May 2, 2023
This week:
Funding
DoorLoop raises USD 100 million in Series B funding at USD 500 million valuation
Residential PropTech
Today
Product updates
Marqeta launches Marqeta Flex with Klarna, Affirm, and Branch (1)
FinTech Infrastructure
Yesterday
Partnerships
Universal Music Group partners with Klay Vision to develop ethical AI music-generation model
Generative AI Applications
Yesterday
Partnerships
OneAIChat partners with Haiper AI to launch text-to-video generation feature
Generative AI Applications
Yesterday
Funding
Zilch raises additional GBP 50 million in debt funding from Deutsche Bank
Buy Now, Pay Later
Yesterday
Product updates
Marqeta launches Marqeta Flex with Klarna, Affirm, and Branch
Buy Now, Pay Later
Yesterday
Funding
Armis raises USD 200 million in Series D funding from General Catalyst and Alkeon Capital
Next-gen Cybersecurity
Yesterday
Funding
Filigran raises USD 35 million in Series B funding to drive global expansion
Next-gen Cybersecurity
Yesterday
Funding
Read AI raises USD 50 million in Series B funding to improve product offering and expand workforce
Remote Work Tools
Yesterday
Product updates
AudioCodes Meeting Insights adds Zoom meeting support
Remote Work Tools
Yesterday
Psychedelic Medicine

Psychedelic Medicine

May 2, 2023

Clearmind Medicine partners with IMP Clinical Supply Services

Partnerships

  • Vancouver-based psychedelic drugs company Clearmind Medicine has partnered with IMP Clinical Supply Services to handle the global clinical supply chain for its drug candidate, CMND-100. IMP will ensure the smooth delivery of the drug to clinical sites, adhering to industry standards.

  • The partnership with IMP ensures that Clearmind's clinical trial for CMND-100, aimed at treating alcohol use disorder (AUD), can proceed without delays or supply chain issues. The trial is expected to start in Q2 2023 in the US and Israel and will assess the safety, pharmacokinetics/pharmacodynamics, and efficacy of CMND-100 in reducing drinking patterns and cravings in individuals with AUD. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.